Novo Nordisk, type 2 diabetes
As Novo Nordisk’s injectable diabetes-obesity duo Ozempic and Wegovy grab all the limelight, an oral version of the ...
A study found that prescriptions for GIP/GLP-1 RA drugs may reduce opioid overdose and alcohol intoxication rates in patients ...
On Monday, Novo Nordisk A/S (NYSE:NVO) released the headline results from the SOUL Phase 3 cardiovascular outcomes trial.
WEIGHT-LOSS jabs are the most talked about drugs of the moment. And with new studies popping up almost every week revealing more benefits of these powerful medicines, it’s no wonder appetite ...
Research published in the journal Addiction indicates that GLP-1 drugs like Ozempic may play a crucial role in reducing ...
Novo Nordisk faces growth deceleration but shows promise. Learn more about NVO stock and why its risk/reward profile may ...
In a huge new statistical analysis, researchers have found more evidence than ever that drugs like Ozempic can help curb ...
We recently compiled a list of the 10 Most Promising Future Stocks According to Analysts. In this article, we are going to ...
In just a few years, brand-name injectable drugs such as Ozempic, Wegovy, Mounjaro and Zepbound have rocketed to fame as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback